Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Down 18.3% in October

Carisma Therapeutics, Inc. (NASDAQ:CARM) saw a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 857,500 shares, a drop of 18.3% from the October 15th total of 1,050,000 shares. Currently, 4.0% of the company’s stock are sold short. Based on an average daily volume of 146,200 shares, the days-to-cover ratio is presently 5.9 days.

Analysts Set New Price Targets

Separately, EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th.

Carisma Therapeutics Price Performance

CARM traded down $0.06 on Friday, reaching $0.88. The company’s stock had a trading volume of 238,783 shares, compared to its average volume of 184,739. Carisma Therapeutics has a 1 year low of $0.80 and a 1 year high of $3.16. The business’s 50 day moving average is $0.98 and its 200 day moving average is $1.13. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39.

Carisma Therapeutics (NASDAQ:CARM) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, meeting analysts’ consensus estimates of ($0.31). The firm had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. Research analysts anticipate that Carisma Therapeutics will post -1.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Carisma Therapeutics

Institutional investors have recently modified their holdings of the business. Wexford Capital LP increased its position in Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after buying an additional 15,000 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Carisma Therapeutics in the 2nd quarter worth about $40,000. Barclays PLC lifted its position in Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after purchasing an additional 549,290 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Carisma Therapeutics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock valued at $3,587,000 after purchasing an additional 11,200 shares during the period. Institutional investors own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.